THE SAFETY AND TOLERABILITY OF SORAFENIB IN THE TREATMENT OF EXTENSIVE RENAL CANCER
https://doi.org/10.17650/1726-9776-2009-5-1-19-26
Abstract
The performed study compared the toxic effects caused by the administration of sorafenib with the manifestations that immediately accompanied extensive renal-cell carcinoma. There is evidence that Sorafenib that is a safe and well tolerable agent increases progression-freesurvival.
About the Authors
V. A. Biryukov
Medical Radiology Research Center, Obninsk
Russian Federation
Russian Federation
O. B. Karyakin
Medical Radiology Research Center, Obninsk
Russian Federation
Russian Federation
References
1. Strumberg D., Awada A., Hirte H. et al.Pooled safety analysis of BAY 43-9006(sorafenib) monotherapy in patients withadvanced solid tumours: is rash associatedwith treatment outcome? Eur J Cancer2006;42:548—56.
2. Ratain M.J., Eisen T., Stadler W.M. et al. Phase II placebo-controlled random-ized discontinuation trial of sorafenib inpatients with metastatic renal cell carcino-ma. Clin Oncol 2006;24:2505—12.
3. Escudier B., Eisen T., Sradler W.M. et al. Sorafenib in advanced clear-cellrenal-cell carcinoma. N Engl J Med2007;356:125—34.
4. Nagore E., Insa A., Sanmartin O.Antineoplastic therapy-induced palmarplantar erythrodysesthesia («hand-foot»)syndrome. Incidence, recognition andmanagement. Am J Clin Dermatol2000;1:225—34.
5. Robert C., Soria J.C., Spatz A. et al.Cutaneous sides of kinase inhibitors andbloking antibodies. Lancet Oncol2005;6:491—500.
6. Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon alfa inmetastatic renal-cell carcinoma. N Engl JMed 2007;356:115—24.
Review
For citations:
Biryukov V.A., Karyakin O.B. THE SAFETY AND TOLERABILITY OF SORAFENIB IN THE TREATMENT OF EXTENSIVE RENAL CANCER. Cancer Urology. 2009;5(1):19-26. (In Russ.) https://doi.org/10.17650/1726-9776-2009-5-1-19-26
Views:
563
Email this article 